Women carrying mutations in *BRCA1* or *BRCA2* are at high risk of developing breast cancer (BC) and ovarian cancer with cumulative BC risks to 80 years of 72% (95% CI = 65% to 79%) and 69% (95% CI = 61% to 77%) for *BRCA1* and *BRCA2* mutation carriers, respectively ([@pky078-B1]). For women in the general population, it is well established that those who had their first full-term pregnancy (FTP) at a young age (\<30 years) have a lower risk of BC than nulliparous women or women who had their first FTP after age 30 years; additional FTPs are associated with even lower risks ([@pky078-B2]). The consistent association between the number of pregnancies and long-term reduction in BC risk is restricted to FTPs ([@pky078-B3]), as incomplete pregnancies (IP) have not been associated with BC risk \[eg, ([@pky078-B3])\]. While FTPs are associated with a reduced BC risk in the long-term, a short-term increase in BC risk has been consistently observed for women following an FTP ([@pky078-B6]), which may be reduced by breastfeeding ([@pky078-B4],[@pky078-B9]). Thus, in addition to being related to long-term risk reduction, breastfeeding might mitigate a short-term increase in BC risk after FTP ([@pky078-B10]).

Given the earlier age at which BC risk increases for women carrying a *BRCA1* or *BRCA2* (*BRCA1/2*) mutation, it is important to know whether the BC risk for carriers is modified by the number and timing of their pregnancies and/or by breastfeeding. However, the few studies that assessed associations with pregnancies and breastfeeding for *BRCA1/2* mutation carriers have reported inconsistent results \[for reviews, see ([@pky078-B11],[@pky078-B12])\], ranging from studies supporting a decreased risk from FTP ([@pky078-B13],[@pky078-B14]) to studies supporting no association ([@pky078-B15]) to studies supporting an increased risk ([@pky078-B16]). Although more limited in numbers, studies that examined *BRCA1 *and* BRCA2* mutation carriers separately have supported differences in associations by mutation type \[eg, higher risk for late age at first FTP or parity in general for *BRCA2* mutation carriers ([@pky078-B13],[@pky078-B16]) and lower risk for multiparity for *BRCA1* mutation carriers ([@pky078-B16]) and differences based on breastfeeding ([@pky078-B17])\].

Most studies of *BRCA1 *and* BRCA2* mutation carriers have been retrospective and the few prospective studies have had limited power to examine *BRCA1* and *BRCA2* mutation carriers separately. To address these issues, we estimated BC risk associations with reproductive history for *BRCA1* and *BRCA2* mutation carriers separately using an international cohort comprised of 9232 and 3886 women in the retrospective and prospective cohorts, respectively.

Methods
=======

Study Sample
------------

We harmonized information from three prospective cohorts, which included 21 national or center-based prospective follow-up studies conducted in Western countries: the International *BRCA1/2* Carrier Cohort Study (IBCCS), the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) Follow-Up Study, and the Breast Cancer Family Registry (BCFR) ([@pky078-B20]). Of the study participants, 84% were enrolled through one of the five major studies: ([@pky078-B1]) Epidemiological Study of Familial Breast Cancer (EMBRACE) in the United Kingdom and Ireland; ([@pky078-B2]) Gene Etude Prospective Sein Ovaire (GENEPSO) in France; ([@pky078-B3]) Hereditary Breast and Ovarian cancer study Netherlands (HEBON) in the Netherlands; ([@pky078-B4]) kConFab in Australia and New Zealand; and ([@pky078-B5]) BCFR in North America and Australia.

Study Participants
------------------

Women were eligible if they were 18--80 years of age and had a known pathogenic *BRCA1* or *BRCA2* mutation. Of the cohort participants, 94% were tested in family clinics and 6% were tested in a research setting, and it was unknown whether or when they opted for a clinical test. We defined two subcohorts for the analyses: ([@pky078-B1]) a prospective cohort comprising women unaffected with BC at baseline, for whom reproductive history data from baseline and, if collected, follow-up questionnaires were combined (2276 *BRCA1* and 1610 *BRCA2* mutation carriers); and ([@pky078-B2]) a retrospective cohort comprising both unaffected and affected women at baseline, for whom only data from the baseline questionnaire were used (5707 *BRCA1* and 3525 *BRCA2* mutation carriers). The kConFab study women were included only in the prospective cohort.

Data Collection
---------------

The baseline and follow-up questionnaires collected detailed information on known or suspected risk factors for BC, including reproductive and medical history and surgical interventions. We collected family history of cancer either from the baseline questionnaire or from pedigrees provided by the genetic counselling centers. We collected information on cancer occurrences, which were confirmed by medical records including pathology records, or through linkage to cancer registries for 92% of all cases. The overall response to the follow-up questionnaires was 73% ([@pky078-B1]). Information on vital status was obtained from municipal, death, or cancer registries or from relatives. Participants provided written informed consent, and each study was approved by a relevant research ethics committee.

Statistical Analysis
--------------------

We used Cox proportional hazards regression models with age as the timescale to calculate hazard ratios (HRs) to assess the association between pregnancy-related variables (ie, parity, number of FTPs, age at first FTP, number of years since last FTP, breastfeeding history and duration of breastfeeding, incomplete pregnancies (IP) due to either spontaneous or induced abortion, timing of IP relative to the first FTP and BC risk), both prospectively (prospective hazard ratio \[HR~P~\]) and retrospectively (retrospective hazard ratio \[HR~R~\]). We conducted separate analyses for *BRCA1* and *BRCA2* mutation carriers. We stratified all analyses for birth cohort (\<1950, 1950--1959, 1960--1969, ≥1970) and for study group (EMBRACE, GENEPSO, HEBON, BCFR, kConFab, and others combined) and used robust variance estimation to account for the inclusion of related women. We assessed whether the findings differed by age using attained age analyses for women based on censoring at age 40 years. We counted pregnancies that occurred at least one year before the age at right censoring to exclude pregnancies that may have occurred at the same time as diagnosis. We adjusted for bilateral oophorectomy as a time-varying covariate in all of the primary analyses and performed sensitivity analyses by including the potential confounders use of oral contraceptives (as a time-varying covariate), age at menarche, and family history of BC.

Retrospective Cohort Analysis
-----------------------------

For retrospective analyses, we modeled time from birth to the diagnosis of first primary BC (invasive or in situ), censoring individuals at the earliest of the following events: diagnosis of any cancer, risk-reducing mastectomy (RRM), or completion of the baseline questionnaire. All covariates were constructed as time-varying covariates. All analyses of the retrospective cohort were performed using the weighted regression approach described by Antoniou et al. ([@pky078-B25]) to allow for the oversampling of affected women; cohort members were weighted so that the observed BC incidences in the study sample were consistent with established BC risk estimates for *BRCA1* and *BRCA2* mutation carriers ([@pky078-B26]). To evaluate potential survival bias, we also performed sensitivity analyses for the retrospective cohort using only pseudo-incident cases in which we considered only the follow-up from 5 years prior to study recruitment to age at censoring.

Prospective Cohort Analysis
---------------------------

For the prospective analysis, we considered follow-up from the date of the baseline questionnaire to the date of diagnosis of any cancer, RRM, last follow-up questionnaire, last information from external source (eg, linkage), age 80 years, or loss to follow-up or death, whichever came first. We included pregnancies and breastfeeding as time-varying covariates.

Combined Cohort Analyses
------------------------

We also conducted a combined analysis using both retrospective and prospective data. We modeled time from birth to the date of diagnosis of any cancer, RRM, last follow-up questionnaire, last information from external source, age 80 years, loss to follow-up or death, whichever came first, with time-dependent weights as described by Antoniou et al. ([@pky078-B25]) for the retrospective period and weights equal to one for the prospective period. Statistical analyses were performed using SAS 9.4.

Results
=======

[Tables 1](#pky078-T1){ref-type="table"} and [2](#pky078-T2){ref-type="table"} summarize the descriptive information for *BRCA1* and *BRCA2* mutation carriers, respectively. Table 1.Characteristics of the *BRCA1* mutation carriers in the retrospective and prospective cohortCharacteristicWomen with breast cancerUnaffected womenRetrospectiveProspectiveRetrospectiveProspective(n = 2544)(n = 269)(n = 3163)(n = 2007)No. (%) or mean (SD)No. (%) or mean (SD)No. (%) or mean (SD)No. (%) or mean (SD)Age at start of follow-up, y---40.6 (10.2)---37.5 (11.8)Age at censure, y40.1 (8.8)44.9 (10.3)39.3 (11.5)43.1 (12.3)Year of birth \<1950805 (31.6)35 (13.0)526 (16.6)205 (10.2) 1950--1959843 (33.1)76 (28.3)646 (20.4)347 (17.3) 1960--1969665 (26.1)104 (38.7)943 (29.8)586 (29.2) ≥1970231 (9.1)54 (20.1)1048 (33.1)869 (43.3)Study group EMBRACE746 (29.3)41 (15.2)814 (25.7)432 (21.5) GENEPSO325 (12.8)46 (17.1)691 (21.8)442 (22.0) HEBON339 (13.3)40 (14.9)463 (14.6)202 (10.1) kConFab---55 (20.4)---270 (13.5) BCFR456 (17.9)50 (18.6)433 (13.7)277 (13.8) Others[\*](#tblfn1){ref-type="table-fn"}678 (26.7)37 (13.8)762 (24.1)384 (19.1)No. of full-term pregnancies (FTP) Nulliparous (no FTP)518 (20.4)51 (19.0)951 (30.1)602 (30.0) 1470 (18.5)43 (16.0)481 (15.2)295 (14.7) 2924 (36.3)113 (42.0)1040 (32.9)652 (32.5) 3430 (16.9)49 (18.2)467 (14.8)292 (14.5) ≥4202 (7.9)13 (4.8)224 (7.1)166 (8.3)Age at 1st full-term pregnancy among parous, y \<20286 (14.1)26 (11.9)244 (11.0)148 (10.5) 20--24830 (41.0)73 (33.5)794 (35.9)482 (34.3) 25--29620 (30.6)73 (33.5)776 (35.1)511 (36.4) ≥30290 (14.3)46 (21.1)398 (18.0)264 (18.8)Years since last full-term pregnancy Nulliparous518 (20.4)51 (19.0)951 (30.1)602 (30.0) 1--5540 (21.2)43 (16.0)665 (21.0)291 (14.5) 6--201078 (42.4)102 (37.9)991 (31.3)662 (33.0) ≥21408 (16.0)73 (27.1)556 (17.6)452 (22.5)Breastfeeding duration among women with full-term pregnancy, mo None594 (29.3)50 (22.9)561 (25.4)311 (22.1) 1--5602 (29.7)59 (27.1)620 (28.0)388 (27.6) 6--12469 (23.1)52 (23.9)544 (24.6)332 (23.6) 13--24244 (12.0)39 (17.9)323 (14.6)243 (17.3) \>24116 (5.7)17 (7.8)159 (7.2)130 (9.3) FTP but stillborn1 (0.0)1 (0.5)5 (0.2)1 (0.1)Incomplete pregnancy (IP) No full-term pregnancy or IP437 (17.2)40 (14.9)825 (26.1)515 (25.7) Full-term pregnancy, no IP1373 (54.0)141 (52.4)1473 (46.6)926 (46.1) Induced abortion only281 (11.0)32 (11.9)334 (10.6)216 (10.8) Miscarriage only383 (15.1)51 (19.0)459 (14.5)295 (14.7) Induced abortion and miscarriage70 (2.8)5 (1.9)72 (2.3)55 (2.7)Incomplete pregnancy relative to first full-term pregnancy No IP1833 (72.1)184 (68.4)2333 (73.8)1458 (72.6) Before first FTP or no FTP359 (14.1)46 (17.1)461 (14.6)330 (16.4) After first FTP352 (13.8)39 (14.5)369 (11.7)219 (10.9)Bilateral oophorectomy No2342 (92.1)131 (48.7)2253 (71.2)1215 (60.5) Yes202 (7.9)138 (51.3)909 (28.7)792 (39.5) Missing001 (0.0)0Oral contraceptive use Never605 (23.8)39 (14.5)653 (20.6)290 (14.4) Ever1820 (71.5)226 (84.0)2352 (74.4)1659 (82.7) Unknown start age69 (2.7)1 (0.4)104 (3.3)6 (0.3) Missing50 (2.0)3 (1.1)54 (1.7)52 (2.6)Age at menarche, y \<12469 (18.4)34 (12.6)452 (14.3)270 (13.5) 12621 (24.4)65 (24.2)836 (26.4)529 (26.4) 13594 (23.3)74 (27.5)745 (23.6)483 (24.1) 14429 (16.9)54 (20.1)598 (18.9)386 (19.2) ≥15380 (14.9)39 (14.5)474 (15.0)313 (15.6) Age missing51 (2.0)3 (1.1)58 (1.8)26 (1.3) Never had menstrual period 0 0 0 0[^2]Table 2.Characteristics of the *BRCA2* mutation carriers in the retrospective and prospective cohortCharacteristicWomen with breast cancerUnaffected womenRetrospectiveProspectiveRetrospectiveProspective(n = 1560)(n = 157)(n = 1965)(n = 1453)No. (%) or mean (SD)No. (%) or mean (SD)No. (%) or mean (SD)No. (%) or mean (SD)Age at start, y45.1 (10.1)40.0 (12.6)Age at censure, y43.4 (9.1)49.0 (10.3)41.5 (12.4)45.0 (13.0)Year of birth \<1950563 (36.1)42 (26.8)386 (19.6)200 (13.8) 1950--1959513 (32.9)44 (28.0)385 (19.6)259 (17.8) 1960--1969387 (24.8)55 (35.0)570 (29.0)433 (29.8) ≥197097 (6.2)16 (10.2)624 (31.8)561 (38.6)Study group EMBRACE615 (39.4)42 (26.8)740 (37.7)441 (30.4) GENEPSO161 (10.3)18 (11.5)437 (22.2)307 (21.1) HEBON91 (5.8)4 (2.5)146 (7.4)71 (4.9) kConFab---38 (24.2)---250 (17.2) BCFR359 (23.0)33 (21.0)322 (16.4)222 (15.3) Others[\*](#tblfn2){ref-type="table-fn"}334 (21.4)22 (14.0)320 (16.3)162 (11.1)No. of full-term pregnancy (FTP) Nulliparous (no FTP)278 (17.8)23 (14.6)537 (27.3)406 (27.9) 1224 (14.4)14 (8.9)288 (14.7)196 (13.5) 2622 (39.9)62 (39.5)631 (32.1)449 (30.9) 3284 (18.2)36 (22.9)330 (16.8)264 (18.2) ≥4152 (9.7)22 (14.0)179 (9.1)138 (9.5)Age at 1st full-term pregnancy among parous, y \<20154 (12.0)11 (8.2)173 (12.1)113 (10.8) 20--24503 (39.2)57 (42.5)550 (38.5)386 (36.9) 25--29408 (31.8)36 (26.9)451 (31.6)347 (33.1) ≥30217 (16.9)30 (22.4)254 (17.8)201 (19.2)Year since last full-term pregnancy Nulliparous278 (17.8)23 (14.6)537 (27.3)406 (27.9) 1--5280 (17.9)16 (10.2)410 (20.9)175 (12.0) 6--20669 (42.9)63 (40.1)590 (30.0)484 (33.3) ≥21333 (21.3)55 (35.0)428 (21.8)388 (26.7)Breastfeeding duration among women with full-term pregnancy None357 (27.8)26 (19.4)408 (28.6)263 (25.1) 1--5 mo342 (26.7)36 (26.9)389 (27.2)255 (24.4) 6--12 mo311 (24.3)34 (25.4)293 (20.5)219 (20.9) 13--24 mo186 (14.5)18 (13.4)220 (15.4)186 (17.8) \>24 mo84 (6.6)20 (14.9)115 (8.1)122 (11.7) FTP but stillborn2 (0.2)03 (0.2)2 (0.2)Incomplete pregnancy (IP) No full-term pregnancy or IP225 (14.4)22 (14.0)471 (24.0)343 (23.6) Full-term pregnancy, no IP850 (54.5)87 (55.4)956 (48.7)680 (46.8) Induced abortion only154 (9.9)10 (6.4)199 (10.1)157 (10.8) Miscarriage only280 (17.9)31 (19.7)284 (14.5)225 (15.5) Induced abortion and miscarriage51 (3.3)7 (4.5)55 (2.8)48 (3.3)Incomplete pregnancy relative to first full-term pregnancy No IP1087 (69.7)110 (70.1)1445 (73.5)1036 (71.3) Before first FTP or no FTP256 (16.4)22 (14.0)270 (13.7)229 (15.8) After first FTP217 (13.9)25 (15.9)250 (12.7)188 (12.9)Bilateral oophorectomy No1430 (91.7)95 (60.5)1522 (77.5)959 (66.0) Yes130 (8.3)62 (39.5)443 (22.5)494 (34.0) Missing0000Oral contraceptive use Never378 (24.2)17 (10.8)412 (21.0)214 (14.7) Ever1106 (70.9)136 (86.6)1452 (73.9)1201 (82.7) Unknown start age46 (2.9)1 (0.6)72 (3.7)5 (0.3) Missing30 (1.9)3 (1.9)29 (1.5)33 (2.3)Age at menarche, y \<12238 (15.3)29 (18.5)337 (17.2)237 (16.3) 12365 (23.4)40 (25.5)503 (25.6)353 (24.3) 13404 (25.9)37 (23.6)454 (23.1)377 (25.9) 14274 (17.6)24 (15.3)336 (17.1)246 (16.9) ≥15247 (15.8)27 (17.2)303 (15.4)214 (14.7) Age missing31 (2.0)030 (1.5)24 (1.7) Never had menstrual period1 (0.1)02 (0.1)2 (0.1)[^3]

BRCA1 Mutation Carriers
-----------------------

For *BRCA1* mutation carriers, there was no overall association of parity compared with nulliparity (combined hazard ratio \[HR~c~\] = 0.99, 95% CI = 0.83 to 1.18) ([Table 3](#pky078-T3){ref-type="table"}). Relative to being uniparous, multiparity was associated with decreased BC risk (HR~c~ = 0.79, 95% CI = 0.69 to 0.91; HR~c~ = 0.70, 95% CI = 0.59 to 0.82; HR~c~ = 0.50, 95% CI = 0.40 to 0.63 for 2, 3, and ≥4 FTPs, respectively, *P*~trend~ \< .0001). The reduced risk associated with multiparity was still evident after adjusting for age at FTP and other risk factors. Each additional FTP after the first was associated with a 16% (95% CI = 11% to 21%) and 26% (95% CI = 14% to 36%) decreased risk in the retrospective and prospective analyses, respectively. [Figure 1](#pky078-F1){ref-type="fig"} shows the probability of developing BC for the prospective cohort. This decreasing risk with increasing parity was evident across all birth cohorts ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, available online). Table 3.Retrospective, prospective, and combined analyses for the *BRCA1* mutation carriersCharacteristic Retrospective*P*~trend~[\*](#tblfn3){ref-type="table-fn"}Prospective*P*~trend~[\*](#tblfn3){ref-type="table-fn"}Combined*P*~trend~[\*](#tblfn3){ref-type="table-fn"}HR (95% CI)HR (95% CI)HR (95% CI)Parous (at least 1 full-term pregnancy)[†](#tblfn4){ref-type="table-fn"} NoReferentReferentReferent Yes0.87 (0.72 to 1.05)1.41 (0.94 to 2.10)0.99 (0.83 to 1.18)No. of full-term pregnancy[†](#tblfn4){ref-type="table-fn"} (FTP) Nulliparous (no FTP)ReferentReferentReference 10.98 (0.81 to 1.20)\<.00011.69 (1.09 to 2.62)\<.00011.11 (0.92 to 1.34)\<.0001 20.77 (0.63 to 0.95)1.25 (0.81 to 1.95)0.88 (0.73 to 1.07) 30.68 (0.53 to 0.86)1.15 (0.70 to 1.90)0.77 (0.62 to 0.97) ≥40.54 (0.40 to 0.73)0.52 (0.27 to 1.02)0.56 (0.42 to 0.74) 1ReferentReferent\<.0001Reference\<.0001 20.78 (0.68 to 0.91)\<.00010.74 (0.51 to 1.08)0.79 (0.69 to 0.91) 30.69 (0.58 to 0.82)0.68 (0.44 to 1.05)0.70 (0.59 to 0.82) ≥40.55 (0.43 to 0.70)0.31 (0.17 to 0.57)0.50 (0.40 to 0.63) Nulliparous1.02 (0.83 to 1.24)0.59 (0.38 to 0.92) 0.90 (0.75 to 1.09)No. of full-term pregnancy by attained age[†](#tblfn4){ref-type="table-fn"} \<40 years  1Referent Referent.22Reference\<.0001  20.73 (0.61 to 0.87)\<.00011.08 (0.61 to 1.91)0.79 (0.66 to 0.94)  30.68 (0.55 to 0.85)0.35 (0.12 to 1.09)0.65 (0.52 to 0.82)  ≥40.63 (0.45 to 0.87)0.67 (0.20 to 2.27)0.64 (0.46 to 0.89) ≥40 years  1Referent\<.0001Referent\<.0001Reference\<.0001  20.82 (0.66 to 1.03)0.61 (0.38 to 0.99)0.78 (0.64 to 0.96)  30.68 (0.54 to 0.87)0.69 (0.41 to 1.16)0.70 (0.56 to 0.88)  ≥40.52 (0.39 to 0.70)0.24 (0.12 to 0.48)0.46 (0.34 to 0.61)Age at 1st full-term pregnancy, y[‡](#tblfn5){ref-type="table-fn"} \<20Referent.03Referent.95Reference.06 20--240.98 (0.81 to 1.19)0.84 (0.54 to 1.30)0.95 (0.80 to 1.13) 25--290.87 (0.71 to 1.06)0.80 (0.52 to 1.23)0.85 (0.71 to 1.02) ≥300.82 (0.65 to 1.04)0.95 (0.59 to 1.55)0.86 (0.70 to 1.07)Year since last full-term pregnancy[§](#tblfn6){ref-type="table-fn"} 0--5Referent.02Referent.002Reference.0002 6--201.19 (1.03 to 1.36)0.89 (0.59 to 1.35)1.14 (0.99 to 1.30) ≥211.48 (1.17 to 1.87)1.12 (0.63 to 1.98)1.44 (1.15 to 1.81) Nulliparous1.05 (0.86 to 1.29)0.55 (0.33 to 0.89)0.92 (0.76 to 1.11) NulliparousReferent Referent Reference  0--50.95 (0.78 to 1.16).021.84 (1.13 to 2.99).0021.09 (0.90 to 1.32).0002 6--201.13 (0.90 to 1.41)1.64 (1.02 to 2.64)1.24 (1.01 to 1.52) ≥211.41 (1.06 to 1.87)2.06 (1.12 to 3.79)1.57 (1.20 to 2.06)Year since last full-term pregnancy by number of full-term pregnancy[†](#tblfn4){ref-type="table-fn"} 1 FTP, 0--5ReferentReferentReference ≥2 FTP, 0--50.65 (0.53 to 0.80)0.75 (0.38 to 1.47)0.68 (0.55 to 0.84) 1 FTP, 6--200.94 (0.73 to 1.20)0.96 (0.47 to 1.95)0.95 (0.75 to 1.21) ≥2 FTP, 6--200.84 (0.67 to 1.04)0.65 (0.33 to 1.30)0.82 (0.66 to 1.03) 1 FTP, ≥211.55 (1.09 to 2.21)1.22 (0.48 to 3.07)1.55 (1.11 to 2.17) ≥2 FTP, ≥210.96 (0.72 to 1.30)0.81 (0.36 to 1.84)0.98 (0.73 to 1.31)Breastfeeding duration[‖](#tblfn7){ref-type="table-fn"} NoneReferent.0002Referent.28Reference.0003 1--5 mo0.96 (0.82 to 1.12)1.07 (0.73 to 1.56)0.97 (0.84 to 1.11) 6--12 mo0.81 (0.69 to 0.95)1.04 (0.70 to 1.54)0.84 (0.72 to 0.97) 13--24 mo0.75 (0.61 to 0.91)1.05 (0.68 to 1.63)0.80 (0.67 to 0.95) \> 24 mo0.64 (0.48 to 0.86)0.75 (0.44 to 1.31)0.66 (0.50 to 0.87)No. of full-term pregnancy and breastfeeding[†](#tblfn4){ref-type="table-fn"} NulliparousReferentReferentReference 1 FTP, never breastfeeding1.15 (0.89 to 1.49)2.01 (1.14 to 3.55)1.33 (1.04 to 1.70) ≥2 FTP, never breastfeeding0.85 (0.67 to 1.07)1.15 (0.67 to 1.96)0.94 (0.76 to 1.18) 1 FTP, ever breastfeeding0.97 (0.78 to 1.19)1.64 (1.00 to 2.70)1.09 (0.89 to 1.33) ≥2 FTP, ever breastfeeding0.73 (0.59 to 0.89)1.22 (0.79 to 1.90)0.84 (0.69 to 1.02)Incomplete pregnancy[§](#tblfn6){ref-type="table-fn"} (IP) No full-term or incomplete pregnancyReferentReferentReference Full-term pregnancy, no IP0.96 (0.79 to 1.16)1.64 (1.03 to 2.61)1.08 (0.90 to 1.29) Induced abortion only1.02 (0.82 to 1.27)1.72 (1.04 to 2.83)1.15 (0.93 to 1.41) Miscarriage only0.97 (0.78 to 1.21)1.77 (1.09 to 2.87)1.11 (0.91 to 1.36) Induced abortion and miscarriage1.09 (0.77 to 1.55)1.09 (0.40 to 2.94)1.11 (0.80 to 1.55)Incomplete pregnancy relative to first full-term pregnancy[§](#tblfn6){ref-type="table-fn"} No IPReferentReferentReference Before first FTP or no FTP1.05 (0.90 to 1.22)1.02 (0.74 to 1.41)1.04 (0.91 to 1.19) After first FTP1.03 (0.89 to 1.20) 1.32 (0.93 to 1.88) 1.09 (0.94 to 1.25) [^4][^5][^6][^7][^8]

![Probability of developing breast cancer in the prospective cohort by parity. **A)** BRCA1. **B)** BRCA2. **Circles** = nulliparous; plus sign, parity = 1; x, parity = 2; **triangles**, parity = 3; **squares**, parity = 4 or more.](pky078f1){#pky078-F1}

The increased risk from uniparity was only seen in the prospective analysis (HR~p~ = 1.69, 95% CI = 1.09 to 2.62). There was some suggestion that this association was stronger for women who have never breastfed (HR~p~ = 2.01, 95% CI = 1.14 to 3.55; HR~p~ = 1.64, 95% CI = 1.00 to 2.70 for women who did not and did breastfeed, respectively), but these HRs were not statistically different (*P*~heterogeneity~ = .54\]. The increased risk, although not statistically significant (HR~p~ = 1.41, 95% CI = 0.94 to 2.10), for overall parity in the prospective cohort was driven mainly by the difference in nulliparity vs uniparity between the two analyses (HR~p~ = 0.59, 95% CI = 0.38 to 0.92, and HR~R~ = 1.02, 95% CI = 0.83 to 1.24, respectively) because the point estimates of each successive pregnancy compared with uniparity were similar in both the retrospective and prospective analyses. [Supplementary Figure 2](#sup1){ref-type="supplementary-material"} (available online) illustrates the difference based on penetrance for *BRCA1* mutation carriers according to different reproductive life scenarios.

Relative to a recent pregnancy, longer time since last FTP was associated with higher risk in the retrospective analysis. Increasing duration of breastfeeding was associated with decreased BC risk (combined cohort *P*~trend~ = .0003) in the retrospective analysis (*P*~trend~ = .0002), but not in the prospective analysis (*P*~trend~ = .28).

IP was associated with an increased BC risk compared with women without IP or FTP in the prospective analysis (HR~p~ = 1.72, 95% CI = 1.04 to 2.83 and HR~p~ = 1.77, 95% CI = 1.09 to 2.87 for induced abortion only and miscarriage only, respectively), but not in the retrospective analysis (HR~R~ = 1.02, 95% CI = 0.82 to 1.27 and HR~R~ = 0.97, 95% CI = 0.78 to 1.21 for induced abortion only and miscarriage only, respectively). The magnitude of the association with IP was similar to the association for any FTP without IP (HR~p~ = 1.64, 95% CI = 1.03 to 2.61). There was also no difference in association whether the IP was before or after the first FTP in all of the analyses.

BRCA2 Mutation Carriers
-----------------------

For *BRCA2* mutation carriers, parity was associated with a 30% increase in BC risk (HR~c~ = 1.33, 95% CI = 1.05 to 1.69) ([Table 4](#pky078-T4){ref-type="table"}). Multiparity was associated with a decreased BC risk (HR~c~ = 0.72, 95% CI = 0.54 to 0.98 for ≥ 4 vs 1 FTP) in the retrospective analysis (HR~R~ = 0.58, 95% CI = 0.42 to 0.79 for ≥4 vs 1 FTP, *P*~trend~ = .0001), but not in the prospective cohort (HR~p~ = 1.68, 95% CI = 0.83 to 3.39 for ≥4 vs 1 FTP, *P*~trend~ = .41 and *P*~heterogeneity~ = .006) ([Figure 1](#pky078-F1){ref-type="fig"}). Multiparity was associated with a decreased BC risk only prior to age 40 years (HR~R~ = 0.29, 95% CI = 0.16 to 0.52 for ≥4 vs 1 FTP) ([Table 4](#pky078-T4){ref-type="table"}). Table 4.Retrospective, prospective, and combined analyses for the *BRCA2* mutation carriersCharacteristic Retrospective*P*~trend~[\*](#tblfn8){ref-type="table-fn"}Prospective*P*~trend~[\*](#tblfn8){ref-type="table-fn"}Combined*P*~trend~[\*](#tblfn8){ref-type="table-fn"}HR (95% CI)HR (95% CI)HR (95% CI)Parous (at least 1 full-term pregnancy)[†](#tblfn9){ref-type="table-fn"} NoReferentReferentReferent Yes1.26 (0.99 to 1.62)1.44 (0.83 to 2.49)1.33 (1.05 to 1.69)No. of full-term pregnancy[†](#tblfn9){ref-type="table-fn"} (FTP) NulliparousReferentReferentReferent 11.28 (0.98 to 1.67).00011.08 (0.55 to 2.14).411.29 (1.01 to 1.66).005 21.32 (1.00 to 1.73)1.63 (0.91 to 2.92)1.42 (1.09 to 1.85) 31.04 (0.76 to 1.44)1.72 (0.89 to 3.34)1.22 (0.89 to 1.66) ≥40.73 (0.51 to 1.07)1.82 (0.91 to 3.64)0.93 (0.66 to 1.33) 1Referent.0001Referent.41Referent.005 21.03 (0.83 to 1.28)1.51 (0.85 to 2.66)1.10 (0.90 to 1.35) 30.82 (0.63 to 1.06)1.59 (0.83 to 3.04)0.94 (0.74 to 1.20) ≥40.58 (0.42 to 0.79)1.68 (0.83 to 3.39)0.72 (0.54 to 0.98) Nulliparous0.78 (0.60 to 1.02) 0.92 (0.47 to 1.82) 0.78 (0.60 to 0.99) No. of full-term pregnancy by attained age[†](#tblfn9){ref-type="table-fn"} \<40 years  1Referent\<.0001Referent.98Referent.0008  20.81 (0.62 to 1.06)2.36 (0.47 to 11.83)0.88 (0.67 to 1.16)  30.79 (0.56 to 1.13)1.25 (0.14 to 11.55)0.81 (0.56 to 1.19)  ≥40.29 (0.16 to 0.52)1.31 (0.09 to 19.54)0.33 (0.17 to 0.63) ≥40 years  1Referent.005Referent.39Referent.04  21.28 (0.95 to 1.73)1.33 (0.71 to 2.48)1.26 (0.97 to 1.65)  30.96 (0.69 to 1.34)1.51 (0.77 to 2.96)1.07 (0.79 to 1.45)  ≥40.77 (0.53 to 1.12)1.57 (0.76 to 3.25)0.90 (0.64 to 1.26)Age at 1st full-term pregnancy, y[‡](#tblfn10){ref-type="table-fn"} \<20Referent.0003Referent.12Referent\<.0001 20--241.13 (0.87 to 1.47)1.60 (0.85 to 2.98)1.25 (0.97 to 1.60) 25--291.39 (1.05 to 1.84)1.26 (0.63 to 2.51)1.39 (1.06 to 1.83) ≥301.64 (1.20 to 2.24)1.95 (0.95 to 3.98)1.77 (1.30 to 2.40)Year since last full-term pregnancy[§](#tblfn11){ref-type="table-fn"}       0--5Referent.57Referent.06Referent.40 6--200.97 (0.79 to 1.18)0.82 (0.42 to 1.59)0.96 (0.79 to 1.17) ≥210.92 (0.67 to 1.25)0.71 (0.31 to 1.64)0.88 (0.65 to 1.19) Nulliparous0.74 (0.56 to 0.97)0.79 (0.35 to 1.77)0.73 (0.56 to 0.94) NulliparousReferent Referent Referent  0--51.36 (1.03 to 1.78).571.27 (0.57 to 2.86).061.37 (1.06 to 1.78).40 6--201.31 (0.98 to 1.76)1.04 (0.51 to 2.14)1.32 (1.01 to 1.74) ≥211.24 (0.86 to 1.79)0.90 (0.38 to 2.15)1.21 (0.86 to 1.70)Breastfeeding duration[§](#tblfn12){ref-type="table-fn"} NoneReferent.002Referent.59Referent.01 1--5 mo1.00 (0.82 to 1.24)1.14 (0.69 to 1.88)1.05 (0.87 to 1.28) 6--12 mo1.16 (0.93 to 1.43)1.28 (0.77 to 2.13)1.17 (0.96 to 1.43) 13--24 mo0.85 (0.66 to 1.09)0.74 (0.40 to 1.35)0.82 (0.64 to 1.04) \> 24 mo0.61 (0.43 to 0.86)1.03 (0.58 to 1.81)0.74 (0.55 to 1.00)No. of full-term pregnancy and breastfeeding[†](#tblfn9){ref-type="table-fn"} NulliparousReferentReferentReferent 1 FTP, never breastfeeding1.33 (0.91 to 1.93)1.90 (0.77 to 4.72)1.45 (1.02 to 2.06) ≥2 FTP, never breastfeeding1.25 (0.91 to 1.72)1.32 (0.66 to 2.65)1.31 (0.98 to 1.77) 1 FTP, ever breastfeeding1.33 (1.00 to 1.78)0.79 (0.35 to 1.80)1.27 (0.98 to 1.66) ≥2 FTP, ever breastfeeding1.19 (0.90 to 1.57)1.71 (0.97 to 3.03)1.35 (1.03 to 1.76)Incomplete pregnancy (IP)[§](#tblfn11){ref-type="table-fn"} No full-term or Incomplete pregnancyReferentReferentReferent Full-term pregnancy, no IP1.35 (1.05 to 1.75)0.82 (0.40 to 1.68)1.28 (1.00 to 1.64) Induced abortion only1.38 (1.01 to 1.89)0.47 (0.18 to 1.17)1.15 (0.85 to 1.56) Miscarriage only1.52 (1.13 to 2.04)0.88 (0.43 to 1.79)1.40 (1.06 to 1.84) Induced abortion and miscarriage1.87 (1.19 to 2.92)0.87 (0.35 to 2.15)1.61 (1.07 to 2.42)Incomplete pregnancy relative to first full-term pregnancy[§](#tblfn11){ref-type="table-fn"} No IPReferentReferentReferent Before first FTP or no FTP1.34 (1.10 to 1.63)0.78 (0.50 to 1.21)1.17 (0.97 to 1.40) After first FTP1.01 (0.82 to 1.24) 0.99 (0.65 to 1.53) 0.99 (0.82 to 1.20) [^9][^10][^11][^12][^13]

We observed an increase in risk with increasing age at first FTP in the retrospective analysis (*P*~trend~ = .0003). There was some suggestion of a similar trend in the prospective cohort (*P*~trend~ = .12; HR~p~ = 1.95, 95% CI = 0.95 to 3.98 for a first FTP at age ≥30 years vs \<20 years). Recent pregnancy was associated with BC risk (≤5 years relative to nulliparous; HR~R~ = 1.36, 95% CI = 1.03 to 1.78; HR~p~ = 1.27, 95% CI = 0.57 to 2.86; HR~c~ = 1.37, 95% CI = 1.06 to 1.78). Increasing duration of breastfeeding was associated with decreased BC risk in the retrospective analysis (*P*~trend~= .002), but not in the prospective cohort (*P*~trend~ = .59). Any pregnancy, including IP, was associated with BC risk but only in the retrospective cohort ([Table 4](#pky078-T4){ref-type="table"}).

We performed sensitivity analyses that further adjusted for age at menarche, oral contraceptive use, and family history of BC or excluding in situ BC. The estimates were very similar to those in the main analysis ([Supplementary Tables 1--3](#sup1){ref-type="supplementary-material"}, available online). Analysis based on the pseudo-incidence retrospective cohort also gave very similar estimates to those based on the entire retrospective cohort ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}, available online).

Discussion
==========

Using data from the largest international cohort study of *BRCA1* and *BRCA2* mutation carriers to date, we found that overall parity was not associated with BC risk for *BRCA1* mutation carriers but was associated with BC risk for *BRCA2* mutation carriers. Nulliparous and multiparous *BRCA1* mutation carriers had lower BC risk compared with uniparous women. Longer duration of breastfeeding also was associated with a reduced risk for *BRCA1* mutation carriers. There was some suggestion that uniparous women who subsequently breastfed may have a decrease in BC risk compared with those that did not. for *BRCA2* mutation carriers, multiparity reduced risk, particularly prior to age 40 years, and late age at first FTP was associated with increased risk.

Previous epidemiological studies investigating modifiable factors for *BRCA1* and *BRCA2* mutation carriers have had limited power to examine gene-specific associations and have primarily been retrospective ([@pky078-B8],[@pky078-B11],[@pky078-B19]). Our cohort provides the first large-scale prospective evaluation of parity separately for *BRCA1* and *BRCA2* mutation carriers. Overall, we found that increasing parity beyond the first child was associated with a decrease in BC risk for *BRCA1* mutation carriers in both the retrospective and prospective analyses. This association with multiparity in *BRCA1* mutation carriers was consistent with a meta-analysis that reported a 17% decrease for each additional birth ([@pky078-B11]). Curiously, however, nulliparity was associated with a reduced risk of BC in comparison with uniparity; this association was particularly marked in the prospective analysis.

Increasing age at FTP was associated with reduced BC risk for *BRCA1* mutation carriers but only in the retrospective analysis. Moreover, the effect size was smaller than that reported in the meta-analysis by Friebel et al. ([@pky078-B11]) (for pregnancy after age 30 years vs before 25 years, relative risk \[RR\] = 0.65, 95% CI = 0.42 to 0.99). The pattern of association is clearly different from that seen in the general population, where increased age at first FTP is associated with increased BC risk ([@pky078-B27]).

For *BRCA2* mutation carriers, we observed a positive association with overall parity in both the retrospective and prospective analyses not driven by uniparity as observed for *BRCA1* mutation carriers. We also observed an increased risk of BC with later age at first FTP, which is more consistent with the association seen in the general population, but in contrast to the results of the Friebel et al. ([@pky078-B11]) meta-analysis, which found no association. We also found an association between multiparity and a reduced risk of BC particularly for women who had four or more pregnancies in the retrospective analysis. We also observed a modest increase in risk associated with recent pregnancies (≤5 years, relative to nulliparous) in *BRCA2* mutation carriers in both retrospective and prospective analyses (36% and 27%, respectively). for *BRCA1* mutation carriers, the risk was also higher in the first five years, relative to nulliparous women, but this was observed only in the prospective cohort. However, there was no difference by attained age even in the prospective analysis where women are slightly older and no evidence that BC risk declined by time since pregnancy, and in opposite, the risk increased with time since last pregnancy in both the retrospective and prospective cohorts.

Although multiparity relative to nulliparity reduced risk in both *BRCA1* and *BRCA2* mutation carriers, late age at first FTP was only associated with increased risk for *BRCA2* mutation carriers. The differences we observed between *BRCA1* and *BRCA2* mutation carriers might reflect their difference in the estrogen receptor (ER) status distribution that has been reported by mutation type ([@pky078-B28]). We did not have hormonal receptor status for our pooled cohort, but we expect the differences we observed reflect both hormonal status as well as age-related differences between *BRCA1* and *BRCA2* mutation carriers. For example, as we recently reported, *BRCA1* and *BRCA2* mutation carriers have different BC risk distributions. For *BRCA1* mutation carriers, there is a rapid increase in BC incidence until ages 30 to 40 years, whereas the risk for *BRCA2* mutation carriers continues to increase until approximately age 50 years, similar to the distribution in the general population ([@pky078-B1]). Therefore, one can expect that risk factors may be different or act differently between *BRCA1* and *BRCA2* mutation carriers because of their timing. In particular, given the later peak in incidence for *BRCA2* mutation carriers, later age at FTP may increase risk in the short-term similar to the transient increase from pregnancy seen in the general population.

Retrospective analyses generally have substantially more power but may be potentially biased for selected risk factors given that risk factors are ascertained after diagnosis, or might motivate study participation. Prospective cohorts have the advantage of collecting information prior to knowing the outcome, but often have more limited statistical power compared to retrospective studies. FTPs, however, are unlikely to have substantial information bias when collected retrospectively, and for prospective analyses, the mean age at start of follow-up has mostly passed the reproductive life period. Similar findings between the two designs also support that selection bias may be less of a concern as selection bias often operates differently in retrospective and prospective studies. We were limited, however, to addressing confounding by only established risk factors that have been collected across all of the studies. We formally tested for homogeneity across the two cohorts using meta-analytic techniques, and both random and fixed effects models suggested that the inferences in both retrospective and prospective analyses were not different from each other. Thus we were able to provide more precise estimates by combining both cohorts. We also investigated heterogeneity across birth cohorts ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, available online) and geographic study sites and observed similar inferences.

The increased risk for uniparous *BRCA1* mutation carriers (and perhaps for *BRCA2* carriers) is inconsistent with the pattern for the general population. However, the lack of a protective effect of parity in *BRCA1* mutation carriers who develop primarily ER-negative tumor is consistent with the weaker association with parity and age at first FTP observed for ER-negative BC in the general population ([@pky078-B28]). It suggests that many of the key driver events may have already occurred in adolescence, such that the first FTP increases the risk of BC due to stimulation of partially transformed mammary cells. This risk may be stronger for first pregnancy for those most susceptible based on prior exposures and then decline after FTP given increased cell differentiation in the late phase of pregnancy and lactation and postpartum gland involution ([@pky078-B29]), thus the lower risk for the uniparous women who breastfeed than women who do not may be explained by the differential rates of mammary gland involution.

Nulliparous and multiparous *BRCA1* mutation carriers have lower BC risk compared with uniparous women. Long duration of breastfeeding decreased risk for *BRCA1* mutation carriers. For *BRCA2* mutation carriers, multiparity seems to reduce risk, although this was limited to the retrospective cohort analyses, and late age at first FTP increased risk. These findings might help refine the BC risk estimates and make it possible to adapt the surveillance of mutation carriers according to their reproductive life history.
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[^1]: See the Notes section for the full list of authors' affiliations.

[^2]: Others included the following studies (at inlusion total number): Medical University of Vienna (MUV) (261), Modifier Study of Quantitative Effects on Disease (MODSQUAD) (228), German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) (178), Lund-BRCA (160), Odense University Hospital (OUH) (105), Hospital Clinico San Carlos (HCSC) (84), INterdisciplinary HEalth Research Internal Team BReast CAncer susceptibility (INHERIT) (66), National Institute of Oncology (NIO) (98), International Hereditary Cancer Center (IHCC) (97), Stockholm-BRCA (71), The Spanish National Cancer Center (CNIO) (40), Milan Italy (33), Hospital Clinico San Carlos (9), German Cancer Research Center (DKFZ) (4), Belgium (3), Dusseldorf Germany (3). EMBRACE = Epidemiological Study of Familial Breast Cancer; GENEPSO = Gene Etude Prospective Sein Ovaire; HEBON = Hereditary Breast and Ovarian cancer study Netherlands; kConFab = Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; BCFR = Breast Cancer Family Registry.

[^3]: Others included the following studies (total number): Medical University of Vienna (MUV) (100), Modifier Study of Quantitative Effects on Disease (MODSQUAD) (80), German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) (105), Lund-BRCA (58), Odense University Hospital (OUH) (62), Hospital Clinico San Carlos (HCSC) (65), INterdisciplinary HEalth Research Internal Team BReast CAncer susceptibility (INHERIT) (74), National Institute of Oncology (NIO) (31), International Hereditary Cancer Center (IHCC) (0), Stockholm-BRCA (13), The Spanish National Cancer Center (CNIO) (44), Milan Italy (12), Hospital Clinico San Carlos (10). EMBRACE = Epidemiological Study of Familial Breast Cancer; GENEPSO = Gene Etude Prospective Sein Ovaire; HEBON = Hereditary Breast and Ovarian cancer study Netherlands; kConFab = Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; BCFR = Breast Cancer Family Registry.

[^4]: Nulliparous excluded, risk factor as continuous.

[^5]: Adjusted for bilateral oophorectomy (Yes, No), age at 1st full-term pregnancy (\<30, ≥30+nulliparous), strata by birth year and study site.

[^6]: Adjusted for bilateral oophorectomy, number of full-term pregnancies (0--1, ≥2), strata by birth year and study site.

[^7]: Adjusted for bilateral oophorectomy, number of full-term pregnancies (0--1, ≥2), age at 1st full-term pregnancy, strata by birth year and study site.

[^8]: Adjusted for bilateral oophorectomy, number of live births (0--1, ≥2), age at 1st full-term pregnancy, strata by birth year and study site.

[^9]: Nulliparous excluded, risk factor as continuous.

[^10]: Adjusted for bilateral oophorectomy (Yes, No), age at 1st full-term pregnancy (\<30, ≥30 nulliparous), strata by birth year and study site.

[^11]: Adjusted for bilateral oophorectomy, number of full-term pregnancies (0--1, ≥2), strata by birth year and study site.

[^12]: Adjusted for bilateral oophorectomy, number of full-term pregnancies (0--1, ≥2), age at 1st full-term pregnancy, strata by birth year and study site.

[^13]: Adjusted for bilateral oophorectomy, number of live births (0--1, ≥2), age at 1st full-term pregnancy, strata by birth year and study site.
